{
    "clinical_study": {
        "@rank": "68880", 
        "acronym": "REMP", 
        "arm_group": [
            {
                "arm_group_label": "Optimization", 
                "arm_group_type": "Experimental", 
                "description": "For optimization of the protocol patients will undergo one DCE-MRI (Gadobutrol), T2* MRI and DWI MRI scan."
            }, 
            {
                "arm_group_label": "Reproducibility", 
                "arm_group_type": "Experimental", 
                "description": "For determination of the reprodicibility patients will undergo two DCE-MRI (Gadobutrol), T2* MRI and DWI MRI scans within one week."
            }
        ], 
        "brief_summary": {
            "textblock": "Novel predictive markers are needed to determine treatment efficacy in pancreatic cancer at\n      an early stage. Preferably, these markers could be determined non-invasively and provide\n      insight into the biology of pancreatic cancer. Several MR techniques can serve for this\n      purpose. However, optimalisation of these techniques is needed and their reproducibility\n      should be assessed."
        }, 
        "brief_title": "Functional Magnetic Resonance Imaging of Pancreatic Cancer: a Feasibility and Reproducibility Study", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Pancreatic Cancer", 
        "condition_browse": {
            "mesh_term": "Pancreatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Background of the study:\n\n      Novel predictive markers are needed to determine treatment efficacy in pancreatic cancer at\n      an early stage. Preferably, these markers could be determined non-invasively and provide\n      insight into the biology of pancreatic cancer. Several MR techniques can serve for this\n      purpose. However, optimalisation of these techniques is needed and their reproducibility\n      should be assessed.\n\n      Objective of the study:\n\n      To optimize DCE-MRI, T2* MRI and DWI in pancreatic cancer at 3T and investigate its\n      reproducibility.\n\n      Study design:\n\n      In the first part of the study, patients with pancreatic cancer will undergo an MR\n      measurement protocol once at 3T, to optimize MR techniques (DCE-MRI, T2* MRI and DWI). In\n      the second part of the study, to assess reproducibility patients will undergo the MR\n      measurement protocol twice within one week before start of any treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with pancreatic tumors, with histological or cytological proof of\n             adenocarcinoma or a high suspicion on CT imaging.\n\n          -  Any tumor with a size \u2265 1cm\n\n          -  WHO-performance score 0-2\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Any psychological, familial, sociological or geographical condition potentially\n             hampering adequate informed consent or compliance with the study protocol.\n\n          -  Contra-indications for MR scanning, including patients with a pacemaker, cochlear\n             implant or neurostimulator; patients with non-MR compatible metallic implants in\n             their eye, spine, thorax or abdomen; or an aneurysm clip in their brain; patients\n             with severe claustrophobia.\n\n          -  Renal failure (GFR < 30 ml/min) hampering safe administration of Gadolinium\n             containing MR contrast agent.\n\n          -  For the reproducibility part of the protocol: surgery, radiation and/or chemotherapy\n             foreseen within the timeframe needed for MRI scanning."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01995240", 
            "org_study_id": "NL40501.018.12"
        }, 
        "intervention": {
            "arm_group_label": [
                "Optimization", 
                "Reproducibility"
            ], 
            "description": "0.1 ml/kg Gadovist is administered at 5 ml/s followed by a 15 ml saline flush", 
            "intervention_name": "Gadobutrol", 
            "intervention_type": "Drug", 
            "other_name": "Gadovist"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "pancreatic cancer", 
            "MRI", 
            "reproducibility", 
            "optimalization"
        ], 
        "lastchanged_date": "December 2, 2013", 
        "location": {
            "contact": {
                "email": "h.vanlaarhoven@amc.uva.nl", 
                "last_name": "Hanneke WM van Laarhoven, M.D., Ph.D.", 
                "phone": "0031 20 5665955"
            }, 
            "facility": {
                "address": {
                    "city": "Amsterdam", 
                    "country": "Netherlands", 
                    "zip": "1105AZ"
                }, 
                "name": "Academic Medical Center"
            }, 
            "investigator": [
                {
                    "last_name": "H WM van Laarhoven, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "R Klaassen, M.Sc.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "2", 
        "official_title": "Functional Magnetic Resonance Imaging of Pancreatic Cancer: a Feasibility and Reproducibility Study", 
        "overall_official": {
            "affiliation": "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)", 
            "last_name": "H WM van Laarhoven, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To assess reproducibility, 15 patients will undergo the MR measurement protocol twice within one week before start of any treatment.\nReproducibility of; DWI: mean ADC of the whole tumor. DCE: mean Ktrans of the whole tumor. T2*: average value of the whole tumor.", 
            "measure": "Reproducibility of DCE, T2* and DWI MRI in pancreatic cancer.", 
            "safety_issue": "No", 
            "time_frame": "Within 1 week"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01995240"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)", 
            "investigator_full_name": "H.W.M. van Laarhoven", 
            "investigator_title": "M.D., Ph.D.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "In those patients for whom tumor tissue is available which has not been treated with radiation or chemotherapy, DCE-MRI, T2* MRI and DWI will be compared with immunohistochemical markers of vascularity, hypoxia and stroma (e.g. CD-31, HIF1-alfa, CA9, GLUT1, PAI-1, VEGF, anti-SMA).", 
                "measure": "Compare in vivo measurements of tumor vascularity, hypoxia and stroma using DCE-MRI, T2* MRI and DWI with immunohistochemically determined markers of vascularity, hypoxia and stroma in pancreatic tumor tissue", 
                "safety_issue": "No", 
                "time_frame": "Within 1 week"
            }, 
            {
                "measure": "To explore the relation between in vivo measurements of tumor vascularity, hypoxia and stroma using DCE-MRI, T2* MRI and DWI and treatment outcome.", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}